Young-Chan Kwon

Dr. Young-Chan Kwon


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 June 2022 in Microbiology Spectrum
Verified
Journal Article
Open access
GJGi Uk Jeong
Gi Uk Jeong
JLJaemyun Lyu
Jaemyun Lyu
KKKyun-Do Kim
Kyun-Do Kim
YCYoung Cheul Chung
Young Cheul Chung
GYGun Young Yoon
Gun Young Yoon
YKYoung-Chan Kwon
Young-Chan Kwon
Recent studies reported neurological and cognitive sequelae in patients with COVID-19 months after the viral infection with several symptoms, including ageusia, anosmia, asthenia, headache, and brain fog. Our conclusions raise awareness of COVID-19-related microglia-mediated neurological disorders to develop treatment strategies for the affected patients.

12 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
GJGi Uk Jeong
Gi Uk Jeong
HKHyung-Jun Kwon
Hyung-Jun Kwon
WNWern Hann Ng
Wern Hann Ng
XLXiang Liu
Xiang Liu
HMHyun Woo Moon
Hyun Woo Moon
YKYoung-Chan Kwon
Young-Chan Kwon
Although ocular manifestations are reported in patients with COVID-19, consensus on ocular tropism of SARS-CoV-2 is lacking. Here, we infect K18-hACE2 transgenic mice with SARS-CoV-2 using various routes. We observe ocular manifestation and retinal inflammation with production of pro-inflammatory cytokines in the eyes of intranasally (IN)-infected mice. Intratracheal (IT) infection results in dissemination of the virus from the lungs to the brain and eyes via trigeminal and optic nerves. Ocular and neuronal invasions are confirmed using intracerebral (IC) infection. Notably, the eye-dropped (ED) virus does not cause lung infection and becomes undetectable with time. Ocular and neurotropic distribution of the virus in vivo is evident in fluorescence imaging with an infectious clone of SARS-CoV-2-mCherry. The ocular tropic and neuroinvasive characteristics of SARS-CoV-2 are confirmed in wild-type Syrian hamsters. Our data can improve the understanding regarding viral transmission and clinical characteristics of SARS-CoV-2 and help in improving COVID-19 control procedures.

1 September 2021 in Vaccines
Verified
Journal Article
Open access
PDF file
PMPuna Maya Maharjan
Puna Maya Maharjan
JCJinyeong Cheon
Jinyeong Cheon
JJJiyun Jung
Jiyun Jung
HKHaerim Kim
Haerim Kim
JLJaewon Lee
Jaewon Lee
SCSunghwa Choe
Sunghwa Choe
The current 15-month coronavirus disease-19 (COVID-19) pandemic caused by SARS-CoV-2 has accounted for 3.77 million deaths and enormous worldwide social and economic losses. A high volume of vaccine production is urgently required to eliminate COVID-19. Inexpensive and robust production platforms will improve the distribution of vaccines to resource-limited countries. Plant species offer such platforms, particularly through the production of recombinant proteins to serve as immunogens. To achieve this goal, here we expressed the receptor binding domain (RBD) of the SARS-CoV-2 spike (S) protein in the glycoengineered-tobacco plant Nicotiana benthamiana to provide a candidate subunit vaccine. This recombinant RBD elicited humoral immunity in mice via induction of highly neutralizing antibodies. These findings provide a strong foundation to further advance the development of plant-expressed RBD antigens for use as an effective, safe, and inexpensive SARS-CoV-2 vaccine. Moreover, our study further highlights the utility of plant species for vaccine development.

1 May 2019 in Hepatology
Verified
Journal Article
Open access
PDF file
YKYoung-Chan Kwon
Young-Chan Kwon
KMKeith Meyer
Keith Meyer
GPGuangyong Peng
Guangyong Peng
SCSoumya Chatterjee
Soumya Chatterjee
DHDaniel Fredric Hoft
Daniel Fredric Hoft
Ratna B. RayRatna B. Ray
Ratna B. Ray
A comprehensive strategy to control HCV infection needs a vaccine. Our phase I study with recombinant HCV E1/E2 EnvGPs as a candidate vaccine did not induce a strong immune response in volunteers. We analyzed the interactions of HCV EnvGPs with human monocyte derived macrophages as antigen presenting cells. HCV E2 induced immune regulatory cytokine IL-10 and sCD163 protein expression in macrophages from 7 of 9 blood donors tested. Further, HCV E2 enhanced Stat3 and suppressed Stat1 activation, reflecting macrophage polarization towards M2 phenotype. E2 associated macrophage polarization appeared to be dependent of its interaction with CD81 leading EGFR activation. Additionally, E2 suppressed the expression of C3 complement, similar to HCV exposed dendritic cells, implying potential impairment of immune cell priming. Conclusion: Our results suggest that E2 EnvGP may not be an ideal candidate for HCV vaccine development, and discrete domains within E2 may prove to be more capable of elliciting a protective immune response.

6 March 2021 in Microorganisms
Verified
Journal Article
Open access
PDF file
HSHYE JIN SHIN
HYE JIN SHIN
MKMi-Hwa Kim
Mi-Hwa Kim
JLJoo-Youn Lee
Joo-Youn Lee
IHInsu Hwang
Insu Hwang
GYGun Young Yoon
Gun Young Yoon
CKChonsaeng Kim
Chonsaeng Kim
Zika virus (ZIKV), which is associated with severe diseases in humans, has spread rapidly and globally since its emergence. ZIKV and dengue virus (DENV) are closely related, and antibody-dependent enhancement (ADE) of infection between cocirculating ZIKV and DENV may exacerbate disease. Despite these serious threats, there are currently no approved antiviral drugs against ZIKV and DENV. The NS2B-NS3 viral protease is an attractive antiviral target because it plays a pivotal role in polyprotein cleavage, which is required for viral replication. Thus, we sought to identify novel inhibitors of the NS2B-NS3 protease. To that aim, we performed structure-based virtual screening using 467,000 structurally diverse chemical compounds. Then, a fluorescence-based protease inhibition assay was used to test whether the selected candidates inhibited ZIKV protease activity. Among the 123 candidate inhibitors selected from virtual screening, compound 1 significantly inhibited ZIKV NS2B-NS3 protease activity in vitro. In addition, compound 1 effectively inhibited ZIKV and DENV infection of human cells. Molecular docking analysis suggested that compound 1 binds to the NS2B-NS3 protease of ZIKV and DENV. Thus, compound 1 could be used as a new therapeutic option for the development of more potent antiviral drugs against both ZIKV and DENV, reducing the risks of ADE.

29 June 2023 in Journal of Virology
Verified
Journal Article
Open access
GJGi Uk Jeong
Gi Uk Jeong
SLSumin Lee
Sumin Lee
DKDo Yeon Kim
Do Yeon Kim
JLJaemyun Lyu
Jaemyun Lyu
GYGun Young Yoon
Gun Young Yoon
YKYoung-Chan Kwon
Young-Chan Kwon
Zika virus (ZIKV) associated neurological impairments are an important global health problem. Our results suggest that ZIKV infection in the mouse brain can induce IL-1β-mediated inflammation and complement activation, thereby contributing to the development of neurological disorders.